Intervention

Paliperidone

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting0
Common conditions19
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology AnalysisNCT06060886 · 2023-11-01
UNKNOWN
Substance Misuse To Psychosis for StimulantsNCT03485417 · 2019-06-01
COMPLETED
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This TreatmentNCT03425552 · 2018-03-11
COMPLETED
Long-acting Paliperidone Palmitate Injection and Olanzapine for SchizophreniaNCT02918825 · 2016-09-01
COMPLETED
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)NCT02600741 · 2015-07-24
COMPLETED
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass SpectrometryNCT02462473 · 2015-05-01
TERMINATED
European Long-acting Antipsychotics in Schizophrenia TrialNCT02146547 · 2015-02-01
COMPLETED
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsNCT02307396 · 2015-02-01
COMPLETED
Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01
TERMINATED
Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot StudyNCT01584466 · 2014-01-01
WITHDRAWN
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With SchizophreniaNCT01662310 · 2011-06-01
COMPLETED
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) ScanningNCT00937261 · 2009-07-01
UNKNOWN
Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic ParticipantsNCT00761605 · 2008-04-01
COMPLETED
Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic RemissionNCT00761579 · 2008-04-01
COMPLETED
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic ParticipantsNCT00784238 · 2008-04-01
COMPLETED
PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute SchizophreniaNCT00761189 · 2008-02-01
COMPLETED
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical AntipsychoticsNCT03730857 · 2008-01-01
COMPLETED
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With SchizophreniaNCT00566631 · 2007-07-01
COMPLETED
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With SchizophreniaNCT00473434 · 2007-04-01
COMPLETED
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyNCT00330863 · 2006-05-01
COMPLETED
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.NCT00668837 · 2004-02-01
COMPLETED

Leading sponsors

Trial status mix

COMPLETED16
TERMINATED2
UNKNOWN2
WITHDRAWN1

Phase mix

PHASE49
PHASE36
PHASE23
NA2
PHASE12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.